Running as Interoceptive Exposure for Decreasing Anxiety Sensitivity: Replication and Extension

Sabourin, Brigitte C.; Stewart, Sherry H.; Watt, Margo C.; Krigolson, Olav

doi:10.1080/16506073.2015.1015163

Cited by 26 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LeBouthillier and Asmundson (this issue) conducted an experiment showing that a single bout of aerobic exercise uniquely reduces AS but not IU or distress tolerance.) Sabourin, Stewart, Watt, and Krigolson (this issue) showed that running as interoceptive exposure followed by a 3-day group CBT intervention reduces AS. Hovland, Johansen, Sjøbø, Vøllestad, Nordhus, Pallesen, Havik, Martinsen, and Nordgreen (this issue) describe a feasibility study on combining internet-based cognitive behavior therapy with physical exercise as treatment for panic disorder.…”

mentioning

confidence: 99%

Exercise for Mood and Anxiety Disorders: The State-of-the Science

Powers

Asmundson

Smits

2015

Cognitive Behaviour Therapy

View full text Add to dashboard Cite

mentioning

confidence: 99%

Exercise for Mood and Anxiety Disorders: The State-of-the Science

Powers

Asmundson

Smits

2015

Cognitive Behaviour Therapy

View full text Add to dashboard Cite

“…In treatment research and clinical practice, the HVQ-B can be informative as either a treatment outcome or a process measure. In fact, a recent study compared changes over 20 running IE trials in high versus low AS participants for the three HVQ-B subscales, finding significant differences in patterns of change between these two groups (Sabourin et al, 2012). Furthermore, changes in HVQ scores over time can be used in clinical practice as an educational tool for clients to learn about their own responses to arousal.…”

Section: Discussionmentioning

confidence: 95%

“…Participants in the present study consisted of 50 female undergraduate students who were part of a larger follow-up AS intervention study (Sabourin et al, 2012). Women were selected based on mass screening ASI scores that were 1 SD above or below mean female ASI scores.…”

Section: Methodsmentioning

confidence: 99%

“…The HVQ-B was administered in a recent follow-up study to Sabourin et al (2008;Sabourin, Stewart, Watt, & Krigolson (2012). Whereas in Study 1, we used the long version of the scale to determine which items to retain for the HVQ-B, in Study 2 we assessed the psychometric properties of the HVQ-B when administered as a stand-alone 18-item measure.…”

Section: Studymentioning

confidence: 99%

“…Scores on the 18 items that were retained for the HVQ-B were combined from the MacDonald et al (2000MacDonald et al ( , 2001, Sabourin et al (2008), and Sabourin et al (2012) data sets to conduct a CFA of the HVQ-B's hypothesized three-factor structure.…”

Section: Studymentioning

confidence: 99%

See 2 more Smart Citations

Development and Psychometric Evaluation of a Brief Version of the Hyperventilation Questionnaire: The HVQ-B

Sabourin

Stewart

Watt

et al. 2013

Cognitive Behaviour Therapy

Self Cite

View full text Add to dashboard Cite

The fear of arousal sensations characterizes some anxiety disorders and is a core feature of an established risk factor for anxiety and related disorders (i.e. anxiety sensitivity; Taylor, 1999). Anxiety sensitivity (AS) refers to a fear of anxiety-related bodily sensations stemming from beliefs that these have catastrophic consequences. Interoceptive exposure (IE; repeated exposure to feared arousal sensations) has been shown to decrease AS. The 33-item Hyperventilation Questionnaire (HVQ; Rapee & Medoro, 1994) measures state levels of cognitive, affective, and somatic responses to IE and arousal induction exercises more generally. The aim of the present set of studies was to develop and evaluate a brief version of the HVQ, the HVQ-B, in order to facilitate its use in research and clinical settings. In Study 1, three existing data sets that used the long version of the HVQ were combined to select the items to be retained for the HVQ-B. In Study 2, the 18-item HVQ-B was administered and its psychometric properties were evaluated. In Study 3, a confirmatory factor analysis (CFA) was performed on the 18 items of the HVQ-B. The HVQ-B demonstrated excellent psychometric properties, and accounted for most of the variance of the questionnaire's longer version. CFA indicated a reasonably good fit of the three-factor measurement model. Finally, the HVQ-B was able to distinguish between responses to arousal induction exercises by high versus low AS participants. The HVQ-B is a useful tool to assess cognitive, affective, and somatic responsivity to arousal sensations in both research and practice.

show abstract

Anxiety Disorders

Szuhany

Simon

2022

JAMA

131

View full text Add to dashboard Cite

ImportanceAnxiety disorders have a lifetime prevalence of approximately 34% in the US, are often chronic, and significantly impair quality of life and functioning.ObservationsAnxiety disorders are characterized by symptoms that include worry, social and performance fears, unexpected and/or triggered panic attacks, anticipatory anxiety, and avoidance behaviors. Generalized anxiety disorder (6.2% lifetime prevalence), social anxiety disorder (13% lifetime prevalence), and panic disorder (5.2% lifetime prevalence) with or without agoraphobia are common anxiety disorders seen in primary care. Anxiety disorders are associated with physical symptoms, such as palpitations, shortness of breath, and dizziness. Brief screening measures applied in primary care, such as the Generalized Anxiety Disorder–7, can aid in diagnosis of anxiety disorders (sensitivity, 57.6% to 93.9%; specificity, 61% to 97%). Providing information about symptoms, diagnosis, and evidence-based treatments is a first step in helping patients with anxiety. First-line treatments include pharmacotherapy and psychotherapy. Selective serotonin reuptake inhibitors (SSRIs, eg, sertraline) and serotonin-norepinephrine reuptake inhibitors (SNRIs, eg, venlafaxine extended release) remain first-line pharmacotherapy for generalized anxiety disorder, social anxiety disorder, and panic disorder. Meta-analyses suggest that SSRIs and SNRIs are associated with small to medium effect sizes compared with placebo (eg, generalized anxiety disorder: standardized mean difference [SMD], −0.55 [95% CI, −0.64 to −0.46]; social anxiety disorder: SMD, −0.67 [95% CI, −0.76 to −0.58]; panic disorder: SMD, −0.30 [95% CI, −0.37 to −0.23]). Cognitive behavioral therapy is the psychotherapy with the most evidence of efficacy for anxiety disorders compared with psychological or pill placebo (eg, generalized anxiety disorder: Hedges g = 1.01 [large effect size] [95% CI, 0.44 to 1.57]; social anxiety disorder: Hedges g = 0.41 [small to medium effect] [95% CI, 0.25 to 0.57]; panic disorder: Hedges g = 0.39 [small to medium effect[ [95% CI, 0.12 to 0.65]), including in primary care. When selecting treatment, clinicians should consider patient preference, current and prior treatments, medical and psychiatric comorbid illnesses, age, sex, and reproductive planning, as well as cost and access to care.Conclusions and RelevanceAnxiety disorders affect approximately 34% of adults during their lifetime in the US and are associated with significant distress and impairment. First-line treatments for anxiety disorders include cognitive behavioral therapy, SSRIs such as sertraline, and SNRIs such as venlafaxine extended release.

show abstract

Running as Interoceptive Exposure for Decreasing Anxiety Sensitivity: Replication and Extension

Cited by 26 publications

References 29 publications

Exercise for Mood and Anxiety Disorders: The State-of-the Science

Exercise for Mood and Anxiety Disorders: The State-of-the Science

Development and Psychometric Evaluation of a Brief Version of the Hyperventilation Questionnaire: The HVQ-B

Anxiety Disorders

Contact Info

Product

Resources

About